Citi analyst Patrick Donnelly lowered the firm’s price target on Icon (ICLR) to $120 from $200 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group post the Q4 reports. Citi sees room for upside to the Q1 outlooks if biopharma activity continues to improve. The firm named Agilent its top tools pick, Natera its top diagnostics pick, and Charles River its top contract research organization pick.
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
